Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Lifted by Distillate Capital Partners LLC

Key Points

• Distillate Capital Partners increased its stake in Regeneron by 32.6% to 37,112 shares (about $20.9M) in the quarter, and other large institutions — including Dodge & Cox, AQR, Invesco and Norges Bank — also materially raised positions, leaving 83.31% of the stock held by hedge funds and institutional investors.
• Regeneron beat the quarter with EPS of $11.44 vs. $10.74 expected and revenue of $3.88B (up 2.5% YoY), has a market cap of ~$78.8B and a P/E of 17.94, and recently raised its quarterly dividend to $0.94 (annualized $3.76, yield 0.5%).
• Corporate insiders sold 5,274 shares worth $4.14M in the past 90 days (insiders now own 7.02%), while analysts maintain a consensus Moderate Buy rating with an average target price of $802.27.

Distillate Capital Partners LLC grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 32.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 37,112 shares of the biopharmaceutical company's stock after purchasing an additional 9,129 shares during the period. Regeneron Pharmaceuticals comprises about 1.1% of Distillate Capital Partners LLC's holdings, making the stock its 26th largest position. Distillate Capital Partners LLC's holdings in Regeneron Pharmaceuticals were worth $20,876,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Dodge & Cox grew its stake in shares of Regeneron Pharmaceuticals by 64.6% in the 2nd quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company's stock valued at $2,008,799,000 after buying an additional 1,502,198 shares in the last quarter. Norges Bank bought a new position in Regeneron Pharmaceuticals during the second quarter valued at approximately $628,151,000. AQR Capital Management LLC raised its position in Regeneron Pharmaceuticals by 528.7% during the third quarter. AQR Capital Management LLC now owns 721,354 shares of the biopharmaceutical company's stock valued at $405,596,000 after acquiring an additional 606,612 shares in the last quarter. Invesco Ltd. lifted its stake in Regeneron Pharmaceuticals by 38.0% in the third quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company's stock valued at $834,675,000 after acquiring an additional 408,649 shares during the last quarter. Finally, Loomis Sayles & Co. L P lifted its stake in Regeneron Pharmaceuticals by 18.6% in the second quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company's stock valued at $1,019,062,000 after acquiring an additional 305,089 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Down 0.1%

Regeneron Pharmaceuticals stock opened at $745.77 on Monday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $821.11. The firm has a fifty day moving average price of $769.73 and a two-hundred day moving average price of $695.68. The firm has a market cap of $78.84 billion, a price-to-earnings ratio of 17.94, a P/E/G ratio of 2.00 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping analysts' consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same period in the previous year, the company posted $12.07 earnings per share. The firm's revenue for the quarter was up 2.5% on a year-over-year basis. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were issued a $0.94 dividend. This is an increase from Regeneron Pharmaceuticals's previous quarterly dividend of $0.88. The ex-dividend date of this dividend was Friday, February 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals's payout ratio is 9.05%.

Wall Street Analysts Forecast Growth

REGN has been the topic of several analyst reports. Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Sunday, March 8th. HSBC raised shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a research note on Monday, November 24th. Morgan Stanley upped their price objective on shares of Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the stock an "equal weight" rating in a report on Monday, February 2nd. Oppenheimer reissued an "outperform" rating and set a $865.00 target price (up from $750.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, February 2nd. Finally, Scotiabank raised their target price on Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the company a "sector perform" rating in a report on Monday, November 24th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $802.27.

Insiders Place Their Bets

In other news, Director Bonnie L. Bassler sold 1,500 shares of the firm's stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the sale, the director owned 1,703 shares in the company, valued at approximately $1,362,400. This trade represents a 46.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Huda Y. Zoghbi sold 1,638 shares of the business's stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the transaction, the director directly owned 1,703 shares in the company, valued at $1,330,604.99. This trade represents a 49.03% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 5,274 shares of company stock valued at $4,142,738. Corporate insiders own 7.02% of the company's stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.